

Table 1. Live innate immune cells (mean percentage  $\pm$  sd) according to expression of receptors in the gingival tissue of C57Bl/6 mice submitted to different treatments for 45 days. SHAM (negative control), P+B- (positive control), P-B+ (1101) (*B. breve* 110<sup>1A</sup>), P+B+ (1101) (microbial consortium + *B. breve* 110<sup>1A</sup>), P-B+ (1622) (*B. bifidum* 162<sup>2A</sup>) and P+B+ (1622) (microbial consortium + *B. bifidum* 162<sup>2A</sup>).

GINGIVAL TISSUE IMMUNE CELLS	SHAM	P+B-	P-B+(1101)	P+B+(1101)	P-B+(1622)	P+B+(1622)
LIMPHOCYTES	10.8 $\pm$ 3.4	25.8 $\pm$ 10.3	39.6 $\pm$ 6.4 <sup>*#</sup>	37.6 $\pm$ 9.3 <sup>*#</sup>	35.5 $\pm$ 5 <sup>*</sup>	54.4 $\pm$ 1 <sup>*#^</sup>
CD45 <sup>+</sup>	25.4 $\pm$ 12.7	36.5 $\pm$ 5.8	64.5 $\pm$ 6.2 <sup>*#</sup>	68.6 $\pm$ 13.5 <sup>*#</sup>	33.7 $\pm$ 11.5	54.3 $\pm$ 8.0 <sup>*#^</sup>
CD45 <sup>+</sup> CD3 <sup>+</sup>	8.5 $\pm$ 0.1	8.49 $\pm$ 2.01	9.0 $\pm$ 1.2	10.9 $\pm$ 0.4	11.6 $\pm$ 1.3	16.8 $\pm$ 0
CD45 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>+</sup>	47.5 $\pm$ 6.6	43.7 $\pm$ 5.6	32.3 $\pm$ 0.9	41.8 $\pm$ 4.5 <sup>*#</sup>	68.1 $\pm$ 5.4	52.7 $\pm$ 1.5
CD45 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>-</sup> ROR $\gamma$ t <sup>+</sup>	0.4 $\pm$ 0.4	0.4 $\pm$ 0.3	9.2 $\pm$ 4.3	10.2 $\pm$ 0.0	0.02 $\pm$ 0.0	0.1 $\pm$ 0.03
CD45 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>+</sup> ROR $\gamma$ t <sup>+</sup>	0.3 $\pm$ 0.3	0.1 $\pm$ 0.1	3 $\pm$ 1.9	1.7 $\pm$ 0.05	0.5 $\pm$ 0.2	0.6 $\pm$ 0.02
CD45 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>+</sup> ROR $\gamma$ t <sup>-</sup>	45.7 $\pm$ 6.6	41.4 $\pm$ 5.7	34.1 $\pm$ 4.8	41.7 $\pm$ 3.5	68.3 $\pm$ 5 <sup>*#</sup>	55 $\pm$ 1.6
CD45 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>-</sup> ROR $\gamma$ t <sup>-</sup>	53.4 $\pm$ 7.4	57.9 $\pm$ 5.2 <sup>*</sup>	53.6 $\pm$ 1.4	46.2 $\pm$ 3.4 <sup>&amp;</sup>	31.1 $\pm$ 4.7 <sup>*#</sup>	44.2 $\pm$ 4.1 <sup>*#^</sup>
CD45 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>-</sup> FOXP3 <sup>+</sup>	0.5 $\pm$ 0.2	0.9 $\pm$ 0.7	6.2 $\pm$ 3.3	3.7 $\pm$ 1.0	0.7 $\pm$ 0.2	2.27 $\pm$ 0.41
CD45 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>+</sup> FOXP3 <sup>+</sup>	3.2 $\pm$ 0.2	2.5 $\pm$ 0.04	4.8 $\pm$ 2.5	4.7 $\pm$ 1.0	3.8 $\pm$ 1.1	6.1 $\pm$ 2.3
CD45 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>+</sup> FOXP3 <sup>-</sup>	42.9 $\pm$ 7.2	39.0 $\pm$ 5.6	28.5 $\pm$ 3.4	37.6 $\pm$ 3.1	56.8 $\pm$ 7.5 <sup>#</sup>	37.9 $\pm$ 3.8 <sup>^</sup>
CD45 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>-</sup> FOXP3 <sup>-</sup>	53.3 $\pm$ 6.6	57.4 $\pm$ 4.9	60.4 $\pm$ 2.5	53.9 $\pm$ 3.1	38.5 $\pm$ 6.1 <sup>#</sup>	53.6 $\pm$ 1.1

\* Statistically significant difference in relation to negative control, # Statistically significant difference in relation to positive control P+B-, & Statistically significant difference in relation to the group P-B+ (1101), ^ Statistically significant difference in relation to the group P-B+ (1622). ANOVA, Tukey's multiple comparison, p <0.05%.